alcaftadine
Trade name: Lastacaft
Approved
Jul 28, 2010
Alcaftadine is a broad-spectrum antihistamine displaying a high affinity for histamine H1 and H2 receptors and a lower affinity for H4 receptors. It also exhibits modulatory action on immune cell recruitment and mast cell stabilizing effects. Alcaftadine is an inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated. LASTACAFT® (alcaftadine ophthalmic solution) indicated for the prevention of itching associated with allergic conjunctivitis. — NCATS
Clinical trial activity
13 trials · 6 clinical orgs · 9 marketing orgs
Earliest trial started Sep 1, 2005 (NCT00223951)
Timeline
2000s
- Jan 1, 2005
Vistakon Pharmaceuticals — Earliest Phase 3 Sponsor(trial)
2010s
- Jul 28, 2010
Vistakon Pharmaceuticals — Earliest FDA Approval
- Jul 28, 2010
Allergan — NDA Secondary Org
- Jul 28, 2010
Vistakon Pharmaceuticals — NDA Organization
- Jul 28, 2010
AbbVie — Marketing Organization
- Jul 28, 2010
AbbVie — NDA Secondary Org
- Aug 5, 2010
Braintree Laboratories — NDA Secondary Org
- Sep 24, 2010
Bayer — NDA Secondary Org
- Oct 28, 2010
Sumitomo Dainippon — NDA Secondary Org
- Jan 1, 2012
2020s
- Jun 23, 2023
Eugia Pharma — Marketing Organization
- Mar 1, 2024
Gland Pharma Ltd — Marketing Organization
- Oct 2, 2024
Alembic — Marketing Organization
Indications
Approved for
Mechanism of action
- Histamine H1 receptorANTAGONIST
HRH1 antagonist
Approval history
- approvedJul 28, 2010
Chemistry & pharmacology
SMILES
CN1CCC(CC1)=C2C3=NC=C(C=O)N3CCC4=C2C=CC=C4- Mol. weight
- 307.3895 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Over the Counter
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaAlcaftadine ↗
- NCATS7Z8O94ECSX ↗
- ChEMBLCHEMBL1201747 ↗
Also known as
- 6,11-dihydro-11-(1-methyl-4-piperidinylidene)-5h-imidazo[2,1-b][3]benzazepine-3-carboxaldehyde
- agn-229666
- alacaftadine
- alcaftadina
- alcaftadina
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadine
- alcaftadinum
- alcaftadinum
- lastacaft
- lastacaft
- lastacaft
- lastacaft
- lastacaft
- r89674
- r89674
- r 89674
- r 89674
- r 89674
- r 89674
- r 89674
- r-89674
- r-89674
- vilasta
- vilasta
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02308501 | Phase 4 | Dec 1, 2014 | ORA, Inc. |
| NCT02161146 | Phase 3 | Jun 1, 2014 | Allergan |
| NCT02082262 | Phase 3 | Mar 1, 2014 | Allergan |
| NCT01808768 | Phase 4 | Apr 1, 2013 | Starx Research Center, LLC |
| NCT01732757 | Phase 4 | Nov 1, 2012 | Allergan |
| NCT01754766 | Phase 2 | Oct 1, 2012 | Allergan |
| NCT01470118 | Phase 4 | Oct 1, 2011 | Allergan |
| NCT01390961 | Phase 4 | Aug 1, 2011 | Allergan, Hom, Milton M., OD, FAAO |
| NCT00889330 | Phase 3 | Apr 1, 2009 | Vistakon Pharmaceuticals |
| NCT00364091 | Phase 3 | Aug 1, 2006 | Vistakon Pharmaceuticals |
| NCT00244543 | Phase 3 | Oct 1, 2005 | Johnson and Johnson, Vistakon Pharmaceuticals |
| NCT00241319 | Phase 3 | Oct 1, 2005 | Johnson and Johnson, Vistakon Pharmaceuticals |
| NCT00223951 | Phase 3 | Sep 1, 2005 | ORA, Inc., Vistakon Pharmaceuticals |
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergan | For profit | 6 | 5 | 3 | 2011 |
| Vistakon Pharmaceuticals | For profit | 5 | 5 | 1 | 2005 |
| Johnson and Johnson | For profit | 2 | 0 | 1 | 2005 |
| ORA, Inc. | For profit | 2 | 1 | 2 | 2005 |
| Hom, Milton M., OD, FAAO | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Starx Research Center, LLC | For profit | 1 | 1 | 1 | 2013 |
Marketing (11)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| AbbVie | For profit | MKTG | Jul 28, 2010 |
| AbbVie | For profit | NDA2 | Jul 28, 2010 |
| Alembic | For profit | MKTG | Oct 2, 2024 |
| Allergan | For profit | NDA2 | Jul 28, 2010 |
| Bayer | For profit | NDA2 | Sep 24, 2010 |
| Braintree Laboratories | For profit | NDA2 | Aug 5, 2010 |
| Eugia Pharma | For profit | MKTG | Jun 23, 2023 |
| Gland Pharma Ltd | For profit | MKTG | Mar 1, 2024 |
| Gland Pharma Ltd | For profit | SYN | Mar 1, 2024 |
| Sumitomo Dainippon | For profit | NDA2 | Oct 28, 2010 |
| Vistakon Pharmaceuticals | For profit | NDA | Jul 28, 2010 |